Why BGPT?
logo

Author Claim Review

Examine the evidence base and provenance of specific claims made by authors or groups.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review


     Quick Explanation



    LucΓ­a FernΓ‘ndez-del-RΓ­o (h-index 15, ~926 citations, 37 works per OpenAlex) is a solid mid-career mitochondrial biochemist specializing in coenzyme Q biosynthesis, with strong collaborative output in high-impact journals, though she is rarely first/last author on her most-cited works.


     Long Explanation



    Scientific Profile: LucΓ­a FernΓ‘ndez-del-RΓ­o

    OpenAlex records 37 works, 926 citations, and an h-index of 15, with sustained productivity 2016–2023 and a citation peak in 2023 (~219 that year) . Note the Semantic Scholar-style snippet (h-index 1, 2 papers) is a fragmentary entity split and should not be used to judge her.

    Her domain is CoQ biosynthesis and mitochondrial metabolism. Key contributions: a widely cited 2018 review on CoQ deficiencies (137 citations) ; first-author work showing kaempferol as a CoQ ring precursor ; and middle-author contributions to high-profile studies on NAFLD lysosomal rescue in Nature Communications and ATP synthase reverse-activity inhibition in EMBO Journal .

    Critical Assessment

    Strengths: consistent specialization (CoQ/mitochondria), publication in top-tier journals (JCI, Nature Communications, EMBO J, JASN), strong methodological breadth (metabolomics, respirometry, RNA-seq, mouse genetics β€” e.g., JCI 2026 Abcc6 work with n=6/group tissue-specific knockouts, deposited GEO datasets ). Limitations: she is mostly a middle author on her most-cited papers; first-author leadership is concentrated in reviews and early-career work; citation trajectory dipped in 2024–2026 (few citations on recent papers), though knowledge half-life for 2023–2026 work is short. Blind spots: no verified independent PI status or funding record visible; entity fragmentation inflates uncertainty in metrics.



    Feedback:    

    Updated: October 23, 2026

     BGPT Author Review



    Scientific Quality

    70%

    Solid domain expert in CoQ/mitochondrial biochemistry with h-index 15 and papers in JCI, Nature Communications, and EMBO Journal. However, her influence is largely as a collaborator rather than independent lead; most-cited works have senior authors (Clarke, Bhatt/inside larger groups). Fragmented author records reduce metric confidence. Competent, well-cited, not yet field-leading.



    Communication Quality

    60%

    Reviews (e.g., CoQ deficiencies, CoQ biosynthesis updates) are well-organized and pedagogically valued by the community, indicating clear communication. No evidence of public-facing science communication; assessment rests on technical writing.



    Author Novelty

    60%

    First-author work on kaempferol as a CoQ ring precursor and non-classical ring precursor reviews were genuinely novel within CoQ biosynthesis. Broader work extends rather than overturns paradigms in mitochondrial metabolism.



    Scientific Rigor

    70%

    Associated studies use appropriate controls, multiple models (yeast, mouse, human cells), orthogonal methods (Seahorse, LC-MS, RNA-seq), and data deposition (GEO). Limitations acknowledged in the JCI paper (unidentified hepatic factor, cryoinjury model constraints). Cannot verify her individual experimental contributions within group papers.

     Hypothesis Graveyard



    Semantic Scholar's h-index of 1 reflects author capability β€” falsified: it is an entity-split artifact; OpenAlex consolidates 37 works and h-index 15 for the same ORCID.


    CoQ10 supplementation benefits in APS (her 2017 coauthor paper) generalize to broad populations β€” small unblinded patient samples and surrogate prothrombotic markers prevent causal extrapolation.

     Science Art


    Author Review: Lucia Fernandez Del Rio Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT